Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.4.1.9 - inulosucrase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Asthma
Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation.
Blindness
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Bone Resorption
Protein farnesyltransferase inhibitors.
Breast Neoplasms
Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
Carcinogenesis
A yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimetics.
In vitro and in vivo evaluation of two rational-designed nonpeptidic farnesyltransferase inhibitors on HT29 human colon cancer cell lines.
Carcinoma
Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas.
Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization.
Carcinoma, Basal Cell
Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas.
Carcinoma, Squamous Cell
Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization.
Cardiomegaly
Overexpression of FNTB and the activation of Ras induce hypertrophy and promote apoptosis and autophagic cell death in cardiomyocytes.
Cardiovascular Diseases
New tricks for human farnesyltransferase inhibitor: cancer and beyond.
Choroideremia
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Colorectal Neoplasms
A significant role of lipogenic enzymes in colorectal cancer.
In vitro and in vivo evaluation of two rational-designed nonpeptidic farnesyltransferase inhibitors on HT29 human colon cancer cell lines.
Diabetic Retinopathy
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Endometrial Neoplasms
Fucosyltransferase and alpha-L-fucosidase activities and fucose levels in normal and malignant endometrial tissue.
Endotoxemia
Farnesyltransferase inhibitor, tipifarnib, prevents galactosamine/lipopolysaccharide-induced acute liver failure.
Heart Failure
Overexpression of FNTB and the activation of Ras induce hypertrophy and promote apoptosis and autophagic cell death in cardiomyocytes.
Hepatitis
Protein farnesyltransferase inhibitors.
The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells.
Hepatitis D, Chronic
New tricks for human farnesyltransferase inhibitor: cancer and beyond.
Hyperinsulinism
Dominant negative farnesyltransferase alpha-subunit inhibits insulin mitogenic effects.
Effect of insulin on farnesyltransferase gene transcription and mRNA stability.
Fetal hyperinsulinemia increases farnesylation of p21 Ras in fetal tissues.
Hyperlactatemia
Burn-induced muscle metabolic derangements and mitochondrial dysfunction are associated with activation of HIF-1? and mTORC1: Role of protein farnesylation.
Insulin Resistance
Burn-induced muscle metabolic derangements and mitochondrial dysfunction are associated with activation of HIF-1? and mTORC1: Role of protein farnesylation.
inulosucrase deficiency
Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.
Invasive Fungal Infections
Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens.
Leber Congenital Amaurosis
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Lung Neoplasms
Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.
Lymphoma, T-Cell
Roles of GTP and Rho GTPases in pancreatic islet beta cell function and dysfunction.
Malaria
Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase.
Theoretical Studies on Binding and Specificity Mechanisms of Farnesyltransferase (FTase) and Geranylgeranyl transferase type-I (GGTase-I) Inhibitors by Molecular Modeling.
Multiple Myeloma
Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells.
Neoplasm Metastasis
New tricks for human farnesyltransferase inhibitor: cancer and beyond.
Neoplasms
A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors.
A significant role of lipogenic enzymes in colorectal cancer.
Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug development.
Biochemical changes of mevalonate pathway in human colorectal cancer.
Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Combined p21-activated kinase and farnesyltransferase inhibitor treatment exhibits enhanced anti-proliferative activity on melanoma, colon and lung cancer cell lines.
Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.
Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes.
Effect of farnesyltransferase overexpression on cell growth and transformation.
Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas.
Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.
Farnesyltransferase as a target for anticancer drug design.
Farnesyltransferase inhibitors as anticancer agents: current status.
Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem.
Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.
Farnesyltransferase inhibitors: potential role in the treatment of cancer.
Fucosyltransferase and alpha-L-fucosidase activities and fucose levels in normal and malignant endometrial tissue.
Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes.
Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
In vitro and in vivo evaluation of two rational-designed nonpeptidic farnesyltransferase inhibitors on HT29 human colon cancer cell lines.
Inhibiting the "Undruggable" RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products.
Inhibition of farnesyltransferase reduces angiogenesis by interrupting endothelial cell migration.
Inhibition of human tumor cell growth in vitro and in vivo by a specific inhibitor of human farnesyltransferase: BIM-46068.
Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228.
Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Molecular docking and simulation of Curcumin with Geranylgeranyl Transferase1 (GGTase1) and Farnesyl Transferase (FTase).
Molecular dynamics analysis of a series of 22 potential farnesyltransferase substrates containing a CaaX-motif.
Molecular dynamics simulations on the critical states of the farnesyltransferase enzyme.
New tricks for human farnesyltransferase inhibitor: cancer and beyond.
Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.
Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development.
Protein farnesyltransferase inhibitors.
Ras p21 farnesylation in ultraviolet B radiation-induced tumors in the skin of SKH-1 hairless mice.
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Reaction path of protein farnesyltransferase at atomic resolution.
Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors.
Spongolactams, farnesyl transferase inhibitors from a marine sponge: isolation through an LC/MS-guided assay, structures, and semisyntheses.
Synthesis and anti-migrative evaluation of moverastin derivatives.
Synthesis and conformational analysis of peptide inhibitors of farnesyltransferase.
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.
The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures.
The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics.
The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS.
The Farnesyltransferase Inhibitor LB42708 Suppresses VEGF-induced Angiogenesis by Inhibiting Ras-dependent MAPK and PI3K/Akt Signal Pathways.
The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner.
Theoretical Studies on Binding and Specificity Mechanisms of Farnesyltransferase (FTase) and Geranylgeranyl transferase type-I (GGTase-I) Inhibitors by Molecular Modeling.
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.
Two cytotoxic sesquiterpene lactones from the leaves of Xanthium strumarium and their in vitro inhibitory activity on farnesyltransferase.
Unraveling the Catalytic Pathway of Metalloenzyme Farnesyltransferase through QM/MM Computation.
Virtual screening and pharmacophore studies for ftase inhibitors using Indian plant anticancer compounds database.
[Anti tumor activity of farnesyl transferase inhibitor]
[Inhibitors of isoprenylation of ras p21]
[Tyrosine kinase receptor-ras-ERK signal transduction pathway as therapeutic tarfet in cancer]
Neurofibromatoses
Protein farnesyltransferase inhibitors.
Pancreatic Neoplasms
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Papilloma
Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization.
Parasitic Diseases
Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.
Protein farnesyltransferase inhibitors.
Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase.
Progeria
Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes.
New tricks for human farnesyltransferase inhibitor: cancer and beyond.
Prostatic Neoplasms
Chemistry and biology for the small molecules targeting characteristics of cancer cells.
Inhibition of GGTase I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells.
Retinal Diseases
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Sepsis
Farnesyltransferase inhibitor, tipifarnib, prevents galactosamine/lipopolysaccharide-induced acute liver failure.
Squamous Cell Carcinoma of Head and Neck
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.
Toxoplasmosis
Theoretical Studies on Binding and Specificity Mechanisms of Farnesyltransferase (FTase) and Geranylgeranyl transferase type-I (GGTase-I) Inhibitors by Molecular Modeling.
Vasospasm, Intracranial
Ras protein contributes to cerebral vasospasm in a canine double-hemorrhage model.
Virus Diseases
The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells.